Kinetics of the Humoral Immune Response Measured by Antibody-Dependent Cell-Mediated Cytotoxicity and Neutralization Assays in Genital Herpesvirus Infections

Kinetics of the Humoral Immune Response Measured by Antibody-Dependent Cell-Mediated Cytotoxicity and Neutralization Assays in Genital Herpesvirus Infections

Kinetics of the Humoral Immune Response Measured by Antibody-Dependent Cell-Mediated Cytotoxicity and Neutralization Assays in Genital Herpesvirus Infections
We have constructed recombinant baculoviruses individually expressing seven of the herpes simplex virus type 1 (HSV-1) glycoproteins (gB, gC, gD, gE, gG, gH, and gI). Only eight cases (6.9 per cent) showed a significant change in titer, indicating a virus infection during or shortly before the study. In most instances, convalescent-phase titers to heterologous VZV were reduced by HSV absorption to levels comparable to those in the acute-phase serum, indicating that cross-reacting antibodies were, in fact, responsible for the heterologous antibody titer rises. Only one case (53-year old female) showed high HSV 1 IgM antibody level by ELISA method, so the vestibular neuronitis in this case was assumed to have a close relation to viral infection. Some heterotypic antibody was demonstrable by RIA in CSF, but, with the exception of herpes simplex antibody in a mumps virus infection, titers were markedly lower than those to the infecting virus type. Of the 25 cultures derived from cervical dysplasias, HSV antigens were found in only 3 cultures. Interestingly, in contrast to results in the absence of complement, addition of complement allowed sera from HSV-2 gD-vaccinated subjects to neutralize HSV-1 and HSV-2 clinical and laboratory isolates with equal potency.

For example, if the current year is 2008 and a journal has a 5 year moving wall, articles from the year 2002 are available. Terms Related to the Moving Wall Fixed walls: Journals with no new volumes being added to the archive. Mice immunized with vaccinia/gD showed 100, 100, and 80% protection against lethal infection with HSV-1 at 18, 44, and 60 weeks postimmunization, respectively. Complete: Journals that are no longer published or that have been combined with another title.

You may also like